Release Date: March 31, 2025

Expiration Date: March 31, 2026

Activity Overview

Recently approved anti-vascular endothelial growth factor (anti-VEGF) agents that target additional pathways and offer innovative delivery methods with longer-lasting effects provide advantages over older anti-VEGF agents in managing neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). In this program, expert faculty discuss the roles of ophthalmologists and optometrists in managing nAMD and DME in an evolving treatment landscape, from screening and diagnosis to referral and ongoing patient care.

This educational activity is an archive of the live symposium held on February 14, 2025.

Target Audience

This live educational activity is directed toward optometrists, ophthalmologists, and other eye care professionals.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Describe the limitations of anti-VEGF intravitreal injection therapies in the treatment of nAMD and DME
Summarize the latest clinical evidence supporting the use of novel therapies in the management of nAMD and DME
Integrate current and emerging agents for nAMD and DME into clinical practice to reduce treatment burden
Explain the role of eye care professionals in the optimal management of nAMD or DME

Patient-Centered Treatment Strategies in the Management of nAMD and DME

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is accredited by COPE to provide continuing education to optometrists.

Physicians’ Education Resource^®, LLC designates this activity for a maximum of 1.0 COPE credit.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Patient-Centered Treatment Strategies in the Management of nAMD and DME

GET STARTED WITH THIS PROGRAM:

Related Content

The New DED Toolkit: Innovative Therapies Reshaping Dry Eye Management

Searching for Silence: Corneal Sensitivity Testing in NK

Advancing Presbyopia Care: Patient-Centered Strategies for Pharmacologic Management

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence